Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Monday.
According to Zacks, “Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. Corvus Pharmaceuticals, Inc. is based in Burlingame, California. “
Other equities analysts have also issued research reports about the stock. Cantor Fitzgerald set a $23.00 price objective on shares of Corvus Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, August 6th. Credit Suisse Group AG reiterated a “buy” rating and issued a $25.00 price objective on shares of Corvus Pharmaceuticals in a report on Tuesday, September 27th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Corvus Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $21.60.
Shares of Corvus Pharmaceuticals (NASDAQ:CRVS) opened at 16.39 on Monday. The stock’s 50 day moving average is $14.94 and its 200 day moving average is $14.01. The firm’s market cap is $342.70 million. Corvus Pharmaceuticals has a 52 week low of $9.63 and a 52 week high of $17.77.
Several large investors have recently added to or reduced their stakes in CRVS. BlackRock Investment Management LLC increased its stake in Corvus Pharmaceuticals by 143.0% in the second quarter. BlackRock Investment Management LLC now owns 12,394 shares of the company’s stock valued at $177,000 after buying an additional 7,294 shares during the last quarter. BlackRock Inc. bought a new stake in Corvus Pharmaceuticals during the first quarter valued at $174,000. Emerald Acquisition Ltd. bought a new stake in Corvus Pharmaceuticals during the second quarter valued at $308,000. Nationwide Fund Advisors bought a new stake in Corvus Pharmaceuticals during the second quarter valued at $386,000. Finally, State Street Corp bought a new stake in Corvus Pharmaceuticals during the second quarter valued at $407,000. 82.91% of the stock is owned by institutional investors.
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on the development of agents, which target the immune system to treat patients with cancer. The Company is developing drugs and antibodies that block crucial immune checkpoints, and reprogram immune T-cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corvus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.